DT-Web

DB00186 - Lorazepam


Identification
Name Lorazepam
Accession Number DB00186 (APRD00116)
Type small molecule
Description A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent. [PubChem]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 321.158
Groups approved
Monoisotopic Weight 320.011932988
Pharmacology
Indication For the management of anxiety disorders, and for treatment of status epilepticus.
Mechanism of action Lorazepam binds to an allosteric site on GABA-A receptors, which are pentameric ionotropic receptors in the CNS. Binding potentiates the effects of the inhibitory neurotransmitter GABA, which upon binding opens the chloride channel in the receptor, allowing chloride influx and causing hyperpolerization of the neuron.
Absorption Readily absorbed with an absolute bioavailability of 90% when given orally. When intramuscularly administered, lorazepam is completely and rapidly absorbed. It achieves max serum concentration in 3 hours. The max serum concentration of a 4 mg dose is 48 ng/mL.
Protein binding 91?2% bound to plasma proteins when given parenterally. When given orally, it is 85% bound to plasma proteins.
Biotransformation Lorazepam is hepatically metabolized and is extensively conjugated to the 3-0-phenolic glucuronide. This is an inactive metabolite and is eliminated mainly by the kidneys.
Route of elimination When a single 2 mg oral dose is give to healthy subjects, 88?4% of the administered dose was recovered in urine and 7?2% was recovered in feces. The percent of administered dose recovered in urine as lorazepam glucuronide was 74?4%. Only 0.3% of the dose was recovered as unchanged lorazepam, and the remainder of the radioactivity represented minor metabolites.
Toxicity The most important clinical adverse event caused by lorazepam is respiratory depression. LD50, mouse, oral = 1850 mg/kg.
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Clozapine Increased risk of toxicity
Kava Kava may increase the effect of the benzodiazepine, lorazepam.
Triprolidine The CNS depressants, Triprolidine and Lorazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
Valproic Acid Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity.
Food Interactions
  • Take with food.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid alcohol.

Targets


Gamma-aminobutyric-acid receptor subunit alpha-1
Name Gamma-aminobutyric-acid receptor subunit alpha-1
Gene Name GABRA1
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.2734
Gamma-aminobutyric-acid receptor subunit alpha-2
Name Gamma-aminobutyric-acid receptor subunit alpha-2
Gene Name GABRA2
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.2049
Gamma-aminobutyric-acid receptor subunit alpha-3
Name Gamma-aminobutyric-acid receptor subunit alpha-3
Gene Name GABRA3
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.2021
Gamma-aminobutyric-acid receptor subunit alpha-4
Name Gamma-aminobutyric-acid receptor subunit alpha-4
Gene Name GABRA4
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 0.8563
Gamma-aminobutyric-acid receptor subunit alpha-5
Name Gamma-aminobutyric-acid receptor subunit alpha-5
Gene Name GABRA5
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.2284
Gamma-aminobutyric-acid receptor subunit alpha-6
Name Gamma-aminobutyric-acid receptor subunit alpha-6
Gene Name GABRA6
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 0.8223
Gamma-aminobutyric-acid receptor subunit beta-1
Name Gamma-aminobutyric-acid receptor subunit beta-1
Gene Name GABRB1
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0834
Gamma-aminobutyric-acid receptor subunit beta-2
Name Gamma-aminobutyric-acid receptor subunit beta-2
Gene Name GABRB2
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0627
Gamma-aminobutyric-acid receptor subunit beta-3
Name Gamma-aminobutyric-acid receptor subunit beta-3
Gene Name GABRB3
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0767
Gamma-aminobutyric acid receptor subunit gamma-1
Name Gamma-aminobutyric acid receptor subunit gamma-1
Gene Name GABRG1
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0726
Gamma-aminobutyric acid receptor subunit gamma-2
Name Gamma-aminobutyric acid receptor subunit gamma-2
Gene Name GABRG2
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0959
Gamma-aminobutyric acid receptor subunit gamma-3
Name Gamma-aminobutyric acid receptor subunit gamma-3
Gene Name GABRG3
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0455
Gamma-aminobutyric acid receptor subunit delta
Name Gamma-aminobutyric acid receptor subunit delta
Gene Name GABRD
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0612
Gamma-aminobutyric acid receptor subunit epsilon
Name Gamma-aminobutyric acid receptor subunit epsilon
Gene Name GABRE
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0594
Gamma-aminobutyric acid receptor subunit pi
Name Gamma-aminobutyric acid receptor subunit pi
Gene Name GABRP
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0362
Gamma-aminobutyric-acid receptor subunit rho-1
Name Gamma-aminobutyric-acid receptor subunit rho-1
Gene Name GABRR1
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0413
Gamma-aminobutyric acid receptor subunit rho-2
Name Gamma-aminobutyric acid receptor subunit rho-2
Gene Name GABRR2
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0471
Gamma-aminobutyric acid receptor subunit rho-3
Name Gamma-aminobutyric acid receptor subunit rho-3
Gene Name GABRR3
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 1.0441
Gamma-aminobutyric acid receptor subunit theta
Name Gamma-aminobutyric acid receptor subunit theta
Gene Name GABRQ
Pharmacological action yes
Actions potentiator
References
  • Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4. - Pubmed
  • Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. - Pubmed
  • Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31. - Pubmed
DTHybrid score 0.6978
Translocator protein
Name Translocator protein
Gene Name TSPO
Pharmacological action unknown
Actions other
References
  • Venneti S, Lopresti BJ, Wiley CA: The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006 Dec;80(6):308-22. Epub 2006 Dec 6. - Pubmed
  • Park CH, Carboni E, Wood PL, Gee KW: Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia. 1996 Jan;16(1):65-70. - Pubmed
  • Uusi-Oukari M, Korpi ER: Specific alterations in the cerebellar GABA(A) receptors of an alcohol-sensitive ANT rat line. Alcohol Clin Exp Res. 1991 Mar;15(2):241-8. - Pubmed
  • Miller EI, Wylie FM, Oliver JS: Detection of benzodiazepines in hair using ELISA and LC-ESI-MS-MS. J Anal Toxicol. 2006 Sep;30(7):441-8. - Pubmed
DTHybrid score 0.6105

Enzymes


UDP-glucuronosyltransferase 2B15
Name UDP-glucuronosyltransferase 2B15
Gene Name Not Available
Actions substrate
References
  • Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, Shin SG: Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94. - Pubmed
DTHybrid score Not Available

Predictions


Id Partner name Gene Name Score
4512 Cytochrome P450 3A4 CYP3A4 0.4361
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.2858
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.2856
918 Glutamate receptor, ionotropic kainate 2 GRIK2 0.2792
921 Glutamate receptor 2 GRIA2 0.2463
6016 Cytochrome P450 2C19 CYP2C19 0.2206
6013 Cytochrome P450 2E1 CYP2E1 0.2116
4757 Cytochrome P450 2C9 CYP2C9 0.1822
6030 Cytochrome P450 2B6 CYP2B6 0.1544
6107 Cytochrome P450 3A7 CYP3A7 0.1362
1588 Multidrug resistance protein 1 ABCB1 0.1319
4118 Cytochrome P450 3A5 CYP3A5 0.1283
4924 Cytochrome P450 2C8 CYP2C8 0.112
6106 Cytochrome P450 2C18 CYP2C18 0.1009
587 Serum albumin ALB 0.0915
4200 Cytochrome P450 1A2 CYP1A2 0.0827
5718 Cytochrome P450 2A6 CYP2A6 0.0619
20 Prostaglandin G/H synthase 1 PTGS1 0.0617
4119 Cytochrome P450 2D6 CYP2D6 0.0546
6102 Arylamine N-acetyltransferase 2 NAT2 0.0515
276 Sodium- and chloride-dependent GABA transporter 1 SLC6A1 0.0493
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0484
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0446
482 Glycine receptor subunit alpha-1 GLRA1 0.0423
6031 Cytochrome P450 3A43 CYP3A43 0.0383
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.036
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0357
6027 Alkaline phosphatase, tissue-nonspecific isozyme ALPL 0.035
461 Glycine receptor subunit alpha-3 GLRA3 0.0344
820 Glycine receptor subunit alpha-2 GLRA2 0.0284
6144 Solute carrier family 22 member 2 SLC22A2 0.0278
6145 Solute carrier family 22 member 1 SLC22A1 0.0236
3937 Fatty-acid amide hydrolase FAAH 0.0228
2981 Phospholipase A2, membrane associated PLA2G2A 0.0182
3426 Glutamine synthetase glnA 0.0182
3987 Glutamine synthetase GLUL 0.0182
6020 Aldehyde oxidase AOX1 0.0174
6024 Cytochrome P450 1A1 CYP1A1 0.0171
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.017
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0159
240 Gamma-aminobutyric acid type B receptor, subunit 1 GABBR1 0.0151
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0146
172 Potassium channel subfamily K member 1 KCNK1 0.0144
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.0138
62 Glycine receptor subunit beta GLRB 0.0132
537 ATP synthase delta chain, mitochondrial ATP5D 0.0132
705 Glutamate receptor 1 GRIA1 0.0127
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0124
489 Monocarboxylate transporter 2 SLC16A7 0.0121
500 Monocarboxylate transporter 4 SLC16A3 0.0118
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0116
738 Monocarboxylate transporter 1 SLC16A1 0.0104
862 Multidrug resistance-associated protein 1 ABCC1 0.0097
1898 Cytochrome P450 1B1 CYP1B1 0.0093
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0091
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0091
468 Cytochrome P450 4A11 CYP4A11 0.0084
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0072
4209 ATP-sensitive inward rectifier potassium channel 8 KCNJ8 0.0069
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.0065
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0065
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0063
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.006
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0055
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.0054
776 Bile salt export pump ABCB11 0.0052
1680 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 0.0049
23 D(1A) dopamine receptor DRD1 0.0046
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.0045
382 Glutamate receptor, ionotropic kainate 1 GRIK1 0.0045
318 Alpha-2A adrenergic receptor ADRA2A 0.0045
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0042
556 Alpha-1A adrenergic receptor ADRA1A 0.0042
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0037
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0034
629 Alpha-2B adrenergic receptor ADRA2B 0.0031
3811 Cytochrome P450 19A1 CYP19A1 0.003
592 Carbonic anhydrase 4 CA4 0.003
502 5-hydroxytryptamine 2A receptor HTR2A 0.0027
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.0023
357 Carbonic anhydrase 2 CA2 0.0021
251 Alcohol dehydrogenase 1A ADH1A 0.0019
465 Calmodulin CALM1 0.0018
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0018
824 Sodium-dependent serotonin transporter SLC6A4 0.0018
444 Alcohol dehydrogenase 1B ADH1B 0.0016
831 D(2) dopamine receptor DRD2 0.0016
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0016
1768 Guanine nucleotide-binding protein G(I)/G(S)/G(O) gamma-2 subunit GNG2 0.0015
1581 G protein-activated inward rectifier potassium channel 2 KCNJ6 0.0015
1268 Neuropeptide S receptor NPSR1 0.0015
1571 G protein-activated inward rectifier potassium channel 1 KCNJ3 0.0015
517 Alcohol dehydrogenase 1C ADH1C 0.0014
6073 Potassium channel subfamily K member 9 KCNK9 0.0014
6072 Potassium channel subfamily K member 3 KCNK3 0.0014
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0012
591 Glutamate [NMDA] receptor subunit 3B GRIN3B 0.0011
837 Glutamate [NMDA] receptor subunit epsilon-1 GRIN2A 0.001
2207 Rhodopsin RHO 0.001
↑